Recurrence in Patients With Differentiated Thyroid Cancer

NCT06154863 | Not Yet Recruiting

• 1 other identifier: recurrence in thyroid cancer
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of this study is to assess the recurrence-free survival (RFS) rate and recurrence-related factors, especially the relationship between RFS and RAI dose, in patients who received RAI after thyroidectomy.

Conditions

Differentiated Thyroid Cancer

Outcome Measures

Primary Outcomes (1)

• Assessment of recurrence-free survival after RAI therapy in patients with thyroid cancer.

  Assessment of recurrence-free survival after radioactive iodine-131 therapy in patients with differentiated thyroid carcinoma.

  2 years

Secondary Outcomes (1)

• Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant.

  2 years

Other Outcomes (3)

• Assessment of Prognostic significance of pathological data post thyroidectomy in thyroid cancer.

  2 years

• Assessment of Prognostic significance of anti-thyroglobulin level in differentiated thyroid cancer.

  2 years

• Assessment of Prognostic significance of thyroglobulin level in differentiated thyroid cancer.

  2 years

Interventions

RAI DRUG

Radioactive iodine

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients with differentiated thyroid cancer underwent total thyroidectomy.

You may qualify if:

• Patients with DTC (differentiated thyroid cancer) who underwent total or subtotal thyroidectomy without distant metastasis and gross residual tumors.
• Followed by ablation with RAI and underwent post RAI whole body scan.
• Having baseline TG (thyroglobulin), Anti-TG antibodies (anti thyroglobulin) and neck US.
• Patients with lymph node metastasis will be included if their lymph nodes had been dissected and no unresectable disease remained.

You may not qualify if:

• Patients who received RAI and missed follow-up.
• Patients with no surgical or pathological data.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (5)

• Vigneri R, Malandrino P, Vigneri P. The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol. 2015 Jan;27(1):1-7. doi: 10.1097/CCO.0000000000000148.

  PMID: 25310641 BACKGROUND

• Sawka AM, Carty SE, Haugen BR, Hennessey JV, Kopp PA, Pearce EN, Sosa JA, Tufano RP, Jonklaas J. American Thyroid Association Guidelines and Statements: Past, Present, and Future. Thyroid. 2018 Jun;28(6):692-706. doi: 10.1089/thy.2018.0070. Epub 2018 Apr 26.

  PMID: 29698130 BACKGROUND

• Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015 Apr;100(4):1529-36. doi: 10.1210/jc.2014-4332. Epub 2015 Feb 2.

  PMID: 25642591 BACKGROUND

• Jeong SY, Lee SW, Kim WW, Jung JH, Lee WK, Ahn BC, Lee J. Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy. Sci Rep. 2019 Apr 3;9(1):5570. doi: 10.1038/s41598-019-42083-3.

  PMID: 30944403 BACKGROUND

• Lee SH, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY, Kim SY. Risk Factors for Recurrence After Treatment of N1b Papillary Thyroid Carcinoma. Ann Surg. 2019 May;269(5):966-971. doi: 10.1097/SLA.0000000000002710.

  PMID: 29462007 BACKGROUND

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 22, 2023
• First Posted: December 4, 2023
• Study Start: March 1, 2024
• Primary Completion: March 1, 2025
• Study Completion: March 1, 2026
• Last Updated: February 20, 2024

Record last verified: 2024-02